224 related articles for article (PubMed ID: 31519562)
1. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
3. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.
Dotti G; Savoldo B; Takahashi S; Goltsova T; Brown M; Rill D; Rooney C; Brenner M
Exp Hematol; 2001 Aug; 29(8):952-61. PubMed ID: 11495701
[TBL] [Abstract][Full Text] [Related]
4. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
5. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
6. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Tuettenberg A; Fondel S; Steinbrink K; Enk AH; Jonuleit H
Exp Dermatol; 2010 Jan; 19(1):44-53. PubMed ID: 19889024
[TBL] [Abstract][Full Text] [Related]
7. Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells.
Servet-Delprat C; Vidalain PO; Bausinger H; Manié S; Le Deist F; Azocar O; Hanau D; Fischer A; Rabourdin-Combe C
J Immunol; 2000 Feb; 164(4):1753-60. PubMed ID: 10657621
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+ Valpha24 natural killer T cells expressing CD40L.
Nieda M; Kikuchi A; nicol A; Koezuka Y; Ando Y; Ishihara S; Lapteva N; Yabe T; Tokunaga K; Tadokoro K; Juji T
Immunology; 2001 Feb; 102(2):137-45. PubMed ID: 11260318
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
10. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
11. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery.
Koya RC; Kasahara N; Favaro PM; Lau R; Ta HQ; Weber JS; Stripecke R
J Immunother; 2003; 26(5):451-60. PubMed ID: 12973034
[TBL] [Abstract][Full Text] [Related]
12. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.
Tomihara K; Kato K; Masuta Y; Nakamura K; Tanaka T; Hiratsuka H; Hamada H
Int J Cancer; 2007 Apr; 120(7):1491-8. PubMed ID: 17205529
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.
Thacker EE; Nakayama M; Smith BF; Bird RC; Muminova Z; Strong TV; Timares L; Korokhov N; O'Neill AM; de Gruijl TD; Glasgow JN; Tani K; Curiel DT
Vaccine; 2009 Nov; 27(50):7116-24. PubMed ID: 19786146
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand.
Vidalain PO; Azocar O; Yagita H; Rabourdin-Combe C; Servet-Delprat C
J Immunol; 2001 Oct; 167(7):3765-72. PubMed ID: 11564793
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-α/CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice.
Shahrokhi S; Daneshmandi S; Menaa F
Hum Gene Ther; 2014 Mar; 25(3):240-53. PubMed ID: 24372569
[TBL] [Abstract][Full Text] [Related]
16. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
17. Differential requirements of T cell subsets for CD40 costimulation in immunity to Blastomyces dermatitidis.
Wüthrich M; Fisette PL; Filutowicz HI; Klein BS
J Immunol; 2006 May; 176(9):5538-47. PubMed ID: 16622023
[TBL] [Abstract][Full Text] [Related]
18. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
Kikuchi T; Moore MA; Crystal RG
Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
[TBL] [Abstract][Full Text] [Related]
20. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
